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ABSTRACT
Background: There is little information on the association of the APOEe4 allele and AD risk in African
populations. In previous analyses from the Indianapolis-Ibadan dementia project, we have reported that
APOE ε4 increased the risk for Alzheimer’s disease (AD) in African Americans but not in Yoruba. This
study represents a replication of this earlier work using enriched cohorts and extending the analysis to include
cognitive decline.
Methods: In this longitudinal study of two community dwelling cohorts of elderly Yoruba and African
Americans, APOE genotyping was conducted from blood samples taken on or before 2001 (1,871 African
Americans & 2,200 Yoruba). Mean follow up time was 8.5 years for African Americans and 8.8 years for
Yoruba. The effects of heterozygosity or homozygosity of ε4 and of the possession of e4 on time to incident
AD and on cognitive decline were determined using Cox’s proportional hazards regression and mixed effects
models.
Results: After adjusting for covariates, one or two copies of the APOE ε4 allele were significant risk factors
for incident AD (p < 0.0001) and cognitive decline in the African-American population (p < 0001). In the
Yoruba, only homozygosity for APOE ε4 was a significant risk factor for AD (p= 0.0002) but not for cognitive
decline (p = 0.2346), however, possession of an e4 allele was significant for both incident AD (p = 0.0489)
and cognitive decline (p = 0.0425).
Conclusions: In this large longitudinal comparative study, APOE ε4 had a significant, but weaker, effect on
incident AD and on cognitive decline in Yoruba than in African Americans. The reasons for these differences
remain unclear.
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Introduction
The APOE ε4 allele is a major risk factor for
Alzheimer Disease (AD) and dementia in most
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populations (Farrer et al., 1997; Chuang et al.,
2010; Ohara et al., 2011). Early studies with African
American cohorts reported inconsistent results
(Farrer et al., 1997; Sahota et al., 1997). However, a
recent meta-analysis has reported that the ε4 allele is
a risk factor for AD in African American populations
with an odds ratio (OR) of 2.31 (Reitz et al.,
2013).
Few studies have examined the role of APOE in
populations with African ancestry in non-African
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countries other than the US and fewer still in
African populations. One study reported the ε4
allele was significantly associated with AD in
African Caribbean people but the magnitude of the
association was small (Stewart et al., 2001) and a
preliminary analysis of cross sectional data from
Kenya suggested that ε4 was not a risk factor for
AD (Chen et al., 2010).
The role of the APOE ε4 allele on cognitive
decline has also been analyzed in samples from
African American cohorts (Kuller et al., 1998;
Knopman et al., 2009; Sawyer et al., 2009). Two
studies have reported that ε4 is a risk factor for
cognitive decline in African Americans with no
discernible differences in effect size when compared
with Caucasian populations (Knopman et al., 2009;
Sawyer et al., 2009). There are no reports of the
effects of ε4 on cognitive decline in African cohorts.
As part of the Indianapolis-Ibadan dementia
project, we have previously reported that possession
of the ε4 allele was associated with a higher risk for
AD for African Americans (Murrell et al., 2006)
whereas ε4 was not associated with increased risk
for AD in Yoruba (Gureje et al., 2006). However,
the sample size was modest (n = 582 for Yoruba,
n = 480 for African Americans) and the analyses
included both prevalent and incident AD patients.
With additional enrichment cohorts and longer
follow-up, we now re-examine this outcome in both
the Indianapolis and Ibadan sample, which includes
a larger number of participants with incident AD.
We also extend the analysis to test whether APOE
ε4 is associated with cognitive decline in both
cohorts.
Methods
Study participants
Since 1992, we have been conducting a com-
parative, community-based epidemiologic study of
prevalence, incidence, and risk factors for AD
in populations of African origin: elderly African
Americans in Indianapolis, Indiana, and Yoruba in
Ibadan, Nigeria. The elderly Yoruba were residents
of the Idikan area and adjacent wards in the more
ancient parts of the city of Ibadan. Residents of
the wards are typically small traders and craftsmen.
Food comes from the local markets that surround
the wards and is mostly locally grown.
A detailed description of the construction of
the original cohorts from 1992 has been previously
reported (Hendrie et al., 2001). In 2001, new study
participants of 70 years and over were recruited.
Recruitment in Ibadan for both the baseline and
enrichment samples involved a total population
survey carried out by means of screening in a
geographically defined area identifying participants
65 years and over at baseline and 70 years and over
in 2001. In Indianapolis, the 65 years and older
self-identified African American baseline cohort was
constructed from a random sample based upon the
1990 census data with addresses being provided
by the Indianapolis Water Company. For the
enrichment sample, the project enrolled additional
community dwelling participants randomly selected
from Medicare records self-identified as African
American and at least 70 years of age. The enriched
sample included in Indianapolis, 1,893 participants
who were added to the 749 survivors of the original
cohort and in Ibadan, 1,939 participants were
added to the 903 survivors. The surviving 1992
cohorts and the newly recruited 2001 cohorts were
similar in basic demographics, age, and gender
(Hendrie et al., 2013). The institutional review
boards of Indiana University School of Medicine
and University of Ibadan approved the study.
Study design
A two-stage design was used at each evaluation with
in-home cognitive and functional evaluations for all
participants followed by a full diagnostic workup
of selected participants based on the performance
of the first stage cognitive tests (Hendrie et al.,
2001). Baseline evaluation was in 1992 for the
original cohorts and in 2001 for the enrichment
cohorts with follow ups occurring in approximately
two to three year intervals (1994, 1998, 2001,
2004, 2007, 2009, and only a screening conducted
in 2011).
Cognitive assessment
The Community Screening Interview for Dementia
(CSID) was used during the first stage in-home
evaluation with a cognitive assessment of the study
participant and an interview with a close relative
evaluating the daily functioning of the participant.
The CSID was developed by our group specifically
for use in comparative epidemiological studies of
dementia in culturally disparate populations (Hall
et al., 2000). The cognitive assessment in CSID
evaluates multiple cognitive domains (language,
attention and calculation, memory, orientation,
praxis, and comprehension and motor response).
For the analysis on cognitive decline, we used
a cognitive score that incorporated all cognitive
items from the screening exam. CSID scores
range from 0 to 80, with higher scores indicating
better cognitive functioning. We also investigated
the CSID memory sub-score which ranged
from 0–29.
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Clinical evaluation
Clinical evaluations included (1) a cognitive
assessment adapted from the Consortium to
Establish a Registry of Alzheimer’s Disease
(CERAD)(Morris et al., 1989); (2) a standardized
clinician examination that included neurologic
and physical exams, and functional status review
(the Clinician Home-based Interview to assess
Function, CHIF) (Hendrie et al., 2006); and (3)
a structured interview recording symptoms and
functional status with a close relative adapted from
the Cambridge Examination for Mental Disorders
of the Elderly informant interview (CAMDEX)
(Hendrie et al., 1988). Following the second stage
of evaluation, participants were diagnosed as having
normal cognitive function or dementia. Diagnosis
was made in a consensus diagnostic conference of
clinicians reviewing the cognitive test results, the
clinician’s assessment, the informant interview, and
available medical records. Dementia was diagnosed
with both the Diagnostic and Statistical Manual of
Mental Disorders, Revised Third Edition (DSM-III-
R)(American Psychiatric Association, 1987) and
International Classification of Diseases, 10th Revision
(ICD-10) (American Pychiatric Association Press,
1992) criteria. AD was diagnosed using criteria
proposed by NINCDS/ADRDA (McKhann et al.,
1984).
Other information
The design of this non-cognitive portion of the
questionnaire was the result of extensive discussion
between the Indianapolis/Ibadan investigators
to identify questions which could be used
harmoniously at both sites and involved a review
of source documents such as CAMDEX (Hendrie
et al., 1988) and CERAD (Morris et al.,
1989). Demographic information including age,
sex and education (years of education for African
Americans, whether or not they attended school for
the Yoruba) were available on all study participants.
Information was also collected on whether the
participant ever consumed alcohol or smoked
regularly. In addition, medical conditions that may
affect cognitive function were collected at each of
the evaluation times. In particular, medical history
of coronary heart disease (CHD), cancer, diabetes,
heart attack, hypertension, Parkinson’s disease,
stroke, and depression were collected from self or
informant reports as affirmative answers to whether
the participants had ever been diagnosed or treated
for these diseases.
Blood samples
DNA was extracted from blood spots collected
on filter paper and from fresh blood using
standard procedures from participants at both
sites who consented to the procedure at or
before 2001. APOE genotypes were determined by
Hhal digestion of amplified products (Hixson and
Vernier, 1990). In the African Americans, 1919
(48.2%) out of 3,983 participants without dementia
at baseline had APOE genotyped. In the Yoruba,
2,226 (51.1%) out of 4,353 participants without
dementia at baseline had APOE genotyped.
Analysis
The primary study outcome was time from
baseline to incident AD. Participants with prevalent
dementia were excluded from the analyses. Those
who were not diagnosed with dementia were
censored on the last evaluation date. Since our
follow-up evaluations were conducted at regularly
scheduled short intervals (2 to 3 years), right
censoring can be used instead of interval censoring
(Leffondre et al., 2013). Time of follow-up was used
as the outcome variable since previous studies have
shown that Cox’s models using time of follow-up
offer more robust results than chronological age in
cohort studies (Chalise et al., 2011).
Participants were divided into three APOE
genotype groups: ε4 homozygotes, ε4 heterozy-
gotes, and non-carriers. A separate analysis of e4
carriers and non-carriers was also conducted.
Also, t-tests and χ2 tests were used to compare
continuous and categorical variables between those
with incident AD and the cognitively normal.
Univariate Cox proportional hazards regression
models were used to identify demographic, life
style, and illness variables significantly associated
with incident AD at the α = 0.15 level within
each site. These were included in multivariable
models where forward and backwards selection
modeling techniques were employed to identify a
final parsimonious model with APOE genotype as
the independent variable and covariates significant
at the α = 0.05 level. Hazard ratios (HR), 95%
confidence intervals (CI) and p-values are reported
from the final models. Kaplan–Meier estimator and
log-rank tests were used to estimate and compare
the distributions of time to incident AD among the
APOE genotype groups in each cohort.
Mixed effects models on repeated CSID scores
over time were used to determine the effect of
APOE genotype on cognitive decline for each site.
An unstructured variance-covariance matrix was
specified. Interactions between APOE and time
since baseline were included in each model, where
significant interaction would indicate differences
in slope, i.e. change over time, by APOE status.
Covariates identified in the Cox’s model on incident
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AD were also included in the mixed effects models
on cognitive decline.
To determine whether our results were subject
to selection bias due to the lack of APOE
genotypes, we compared demographic variables
between participants included in the analyses and
those without APOE genotypes using t-tests and χ2
tests.
Results
There were 1,919 African Americans and 2,226
Yoruba without dementia at baseline who had
APOE genotyped. We excluded 48 African
Americans and 26 Yoruba participants who had
incident non-AD dementia from the analysis.
Incident AD was diagnosed in 182 (9.7%) African
Americans and 1,689 (90.3%) participants were
determined to have normal cognition. Incident AD
was diagnosed in 173 (7.9%) Yoruba participants
and 2,027 (92.1%) were determined to have normal
cognition. Median follow-up was 8.5 years for
the African Americans and 8.8 years for the
Yoruba.
Table 1 compares the baseline characteristics
of the participants with incident AD with the
participants with normal cognition within each
cohort. For the African American cohort, the
participants with incident AD were significantly
more likely to possess at least one copy of the APOE
ε4 allele (p ˂ 0.0001), be older (p = 0.0002), be
less educated (p ˂ 0.0001), and be significantly
more likely to come from the original cohort (p ˂
0.0001). They were also significantly less likely to
report having had diabetes (p = 0.0089) and using
alcohol (p = 0.0049).
For the Yoruba cohort, the participants with
incident AD were marginally more likely to possess
at least one copy of APOE ε4 (p = 0.0537),
significantly more likely to be older (p ˂ 0.0001),
have no education (p = 0.0112), be female (p
˂ 0.0001), and be from the original cohort (p ˂
0.0001). They were also significantly less likely to
report alcohol use (p ˂ 0.0001).
Figure 1 shows the Kaplan-Meier estimates of
the survival function on time to AD for each cohort
based upon the APOE genotypes. Log-rank tests
found a significant difference between the three
APOE groups in both the African Americans (p ˂
0.0001) and in the Yoruba (p = 0.0046).
Table 2 shows the results from the final Cox
proportional hazards regression model on incident
AD for both sites based upon number of APOE ε4
alleles. In the African Americans, after adjusting for
years of education, baseline age, and cohort status,
both APOE ε4 homozygotes and heterozygotes
had significant increased risk of AD compared to
non-carriers (p < 0.0001). In the Yoruba, those
participants homozygous for the ε4 allele had
significantly increased risk for AD compared to non-
carriers after adjusting for age, gender, and history
of smoking (HR= 2.95, p= 0.0002). Notably, there
was a non-significant increase in risk for AD among
those heterozygous for the ε4 allele as compared
with those who did not have an ε4 allele (p =
0.2362). When APOE ε4 carrier status was used
in the Cox models to compare the presence (1 or
2 copies) vs. absence of the APOE ε4 allele, the
presence of the ε4 allele significantly increased the
risk for AD for the African Americans (HR 2.47;
95% CI 1.84–3.32; p < 0.0001) and also for the
Yoruba (HR 1.35; 95% CI 1.00–1.83; p= 0.0489).
Table 3 shows the results from the mixed
effects models on cognitive decline for the two
cohorts for the number of APOE ε4 alleles after
adjusting for the covariates used in the Cox
models. For the African Americans, there was a
significant interaction between time since baseline
and the APOE groups (p < 0.0001) indicating
significantly more decline for both the heterozygote
and homozygote groups than non-carriers (p <
0.001 for both). For the Yoruba, the interaction
was not significant (p>0.05), indicating that the
APOE ε4 allele does not affect cognitive decline
using this model. When APOE ε4 carrier status was
used in the model for cognitive decline, ε4 carriers
had significantly increased risk for cognitive decline
in both the African Americans (p = 0.0001) and in
the Yoruba (p = 0.0425).
When the memory subdomain was analyzed
separately for cognitive decline using the number
of e4 allele model, the results were similar to those
for global cognitive decline (African Americans:
β(ε4 homozygous) = −0.26, p = 0.0004; β(ε4
heterozygous) = −0.07, p = 0.009; Yoruba:
β(ε4 homozygous) = −0.11 p = 0.054, β(ε4
heterozygous) = −0.02 p = 0.25).
African American participants who did not have
APOE genotyped were significantly less educated
(p < 0.0001) and more likely to be male (p =
0.0057). In the Yoruba those without an APOE
genotype were significantly older (p < 0.0001)
than those who were genotyped and included in
this analysis. In both cohorts, participants without
genotyping had slightly lower cognitive scores at
baseline than those who were genotyped (p <
0.0001 for both).
Discussion
In this analysis, the APOE ε4 allele is a significant
risk factor for incident AD in the African American
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Table 1. Baseline characteristics of African-American and Yoruba participants with incident AD and normal
cognition
AFRICAN A MERICANS YORUBA
V A R I A B L E
NAME
NORMAL
COGNITION
(n = 1689)
INCIDENT AD
(n = 182) P-VALUE
NORMAL
COGNITION
(n = 2027)
INCIDENT AD
(n = 173) P-VALUE
............................................................................................................................................................................................................................................................................................................................
Number of APOE
ε4 alleles, n (%)
<.0001 0.0537
0 1128 (66.8%) 88 (48.4%) . 1250 (61.7%) 95 (54.9%) .
1 503 (29.8%) 80 (44.0%) . 685 (33.8%) 64 (37.0%) .
2 58 (3.4%) 14 (7.7%) . 92 (4.5%) 14 (8.1%) .
Age at baseline,
mean±sd
75.52 ± 5.85 77.47 ± 6.69 0.0002 72.99 ± 6.26 75.72 ± 8.79 <.0001
Years of education
(Indianapolis)
mean±sd
/Attended
School (Ibadan)
n (%)
11.02 ± 2.78 9.53 ± 3.37 <.0001 308 (15.2%) 14 (8.1%) 0.0112
Female gender, n
(%)
1132 (67.0%) 131 (72.0%) 0.1750 1307 (64.5%) 142 (82.1%) <.0001
From the 1992
Cohort, n (%)
520 (30.8%) 125 (68.7%) <.0001 1109(54.7%) 138 (79.8%) <.0001
Angina, n (%) 193 (11.5%) 28 (15.4%) 0.1241 156 (7.7%) 12 (6.9%) 0.7180
Anxiety, n (%) 244 (14.5%) 35 (19.3%) 0.0854 31 (1.5%) 1 (0.6%) 0.3158
Depression, n (%) 165 (9.8%) 15 (8.3%) 0.5195 286 (14.1%) 27 (15.6%) 0.5884
Family history of
dementia, n (%)
233 (14.0%) 33 (18.2%) 0.1239 48 (2.4%) 3 (1.7%) 0.5919
Diabetes, n (%) 467 (27.7%) 34 (18.7%) 0.0089 47 (2.3%) 2 (1.2%) 0.3199
Head Injury, n
(%)
153 (9.1%) 10 (5.5%) 0.1006 64 (3.2%) 3 (1.7%) 0.2957
Heart Attack, n
(%)
227 (13.6%) 21 (11.5%) 0.4430 292 (14.4%) 27 (15.6%) 0.6666
Hypertension, n
(%)
1220 (73.0%) 124 (68.1%) 0.1654 469 (23.2%) 33 (19.2%) 0.2283
Parkinsons
Disease, n (%)
11 (0.7%) 0 (0.0%) 0.2743 89 (4.4%) 6 (3.5%) 0.5667
Stroke, n (%) 232 (13.8%) 18 (9.9%) 0.1505 30 (1.5%) 1 (0.6%) 0.3337
Alcohol Use, n
(%)
615 (38.5%) 49 (27.7%) 0.0049 670 (33.4%) 30 (17.6%) <.0001
Smoking History,
n (%)
997 (59.2%) 95 (52.5%) 0.0813 629 (31.0%) 49 (28.3%) 0.4591
Cancer, n (%) 253 (15.1%) 23 (12.6%) 0.3726 18 (0.9%) 3 (1.7%) 0.2719
Heart Problems, n
(%)
509 (30.2%) 44 (24.2%) 0.0931 383 (18.9%) 3 (19.7%) 0.8070
cohort (homozygotes-HR: 4.12, CI: 2.33–7.28;
heterozygotes-HR: 2.31, CI: 1.70–3.14, presence
of an e4 allele, HR 2.47; 95% CI 1.84–3.32; p <
0.0001). These results are consistent with our
previously published results using smaller samples
and with the results of the recently published
Alzheimer Disease Genetic Consortium (ADGC)
study which examined African American cohorts
(Reitz et al., 2013). These data indicate a dose
dependent effect of the APOE ε4 allele on AD risk
in African Americans.
In contrast to our previous findings with Yoruba
where we found no relationship with ε4 and AD
(Gureje et al., 2006), in this analysis we did
detect a significant association for incident AD
with the presence of an APOE e4 allele (HR: 1.35
95%; CI:1.00–1.83). We also found a significant
association with homozygosity but not heterozy-
gosity (homozygotes HR: 2.95, CI: 1.67–5.19;
heterozygotes-HR: 1.21, CI: 0.88–1.67). There are
no other studies of the effect of ε4 on incident AD
in African populations with which to compare.
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Table 2. Results from ﬁnal Cox’s proportional hazards models on incident AD risk for the African American and
Yoruba cohorts
AFRICAN A MERICANS YORUBA
HR 95% CI P-VALUE HR 95% CI P-VALUE
............................................................................................................................................................................................................................................................................................................................
Number of APOE ε4 alleles <0.0001 0.0009
2 vs. 0 4.12 2.33–7.28 <0.0001 2.95 1.67–5.19 0.0002
1 vs. 0 2.31 1.70–3.14 <0.0001 1.21 0.88–1.67 0.2362
Age a baseline 1.13 1.11–1.16 <0.0001 1.10 1.08–1.12 <0.0001
Years of education 0.690 0.85–0.94 <0.0001 N.I. N.I. N.I.
Original cohort 2.55 1.79–3.61 <0.0001 N.I. N.I. N.I.
Female gender N.I. N.I. N.I. 3.12 2.03–4.80 <0.0001
History of smoking N.I. N.I. N.I. 1.60 1.10–2.31 0.0134
N.I.: not included in final model
Figure 1. Kaplan-Meier survival estimates for time to incident AD.
Despite the significant association between
APOE ε4 homozygosity and AD in the Yoruba, the
association between ε4 and AD remains weaker for
Yoruba than for African Americans. There is no
overlap in confidence limits between the 2 cohorts
in the analysis of the effects on AD of the presence
of the e4 alelle It is possible that these differences
in ε4 effect reflect genetic differences between the
two cohorts. The greatest genetic diversity occurs
in Sub-Saharan African populations, including
Nigeria, where it has been estimated that the
genetic variation exceeds that found amongst
European populations (Tishkoff et al., 2009). As
a result, there may be unique variants segregating
in the Nigerian population that may affect protein
function and gene expression that, in turn, interact
with environmental factors such as diet. Many of
these variants are population specific and some
are predicted to affect protein function (Tennessen
et al., 2012), modify chromatin accessibility,
transcription factor binding (Degner et al., 2012)
and DNA methylation levels resulting in gene
expression differences (Bell et al., 2011). Patterns
of genetic variation are shaped by demographic
forces such as migration events, fluctuation in
population size and by evolutionary forces such as
natural selection and mutation. A classic example
of this is the single base mutation in the FY gene
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Table 3. Results from mixed effects models on cognitive decline∗ for both cohorts
AFRICAN A MERICANS YORUBA
P A R A M E T E R
E S T I M A T E
STANDARD
ERROR P-VALUE
P A R A M E T E R
E S T I M A T E
STANDARD
ERROR P-VALUE
......................................................................................................................................................................................................................................................................................................................
Number of APOE ε4 alleles 0.3469 0.9849
2 vs. 0 − 0.90 0.82 0.2727 − 0.11 0.64 0.6221
1 vs. 0 − 0.37 0.34 0.2739 − 0.02 0.28 0.9142
Age at baseline − 0.35 0.03 <0.0001 − 0.30 0.02 <0.0001
Years of education 1.01 0.05 <0.0001 N.I. N.I. N.I.
Original cohort − 1.42 0.32 <0.0001 N.I. N.I. N.I.
Years Since Baseline − 0.75 0.03 <0.0001 − 0.58 0.03 <0.0001
Female gender N.I. N.I. N.I. − 6.95 0.29 <0.0001
History of smoking N.I. N.I. N.I. − 1.79 0.30 <0.0001
Interaction – Number of APOE ε4
alleles and Years Since Baseline
<0.0001 0.1152
2 vs. 0 − 0.48 0.15 0.0009 − 0.13 0.11 0.2346
1 vs. 0 − 0.18 0.06 0.0007 − 0.08 0.04 0.1152
N.I.: not included in final model
∗Cognitive decline was based upon cognitive scores from the Community Screening Interview for Dementia
(DuffyO) that in the homozygous state renders
the individual resistant to malaria. It has been
suggested that APOE has a meat adaptive function
and evolved with an increase in consumption
of animal tissue. The gene is thought to confer
resistance to hypercholesterolemia and infections
(Finch and Sapolsky, 1999; Finch and Stanford
2004) Another theory is that the ε4 allele would be
advantageous under seasonal periods of starvation,
due to its elevating effect of cholesterol which
would otherwise be too low but detrimental in
areas where animal fats were readily available
(Corbo and Scacchi, 1999). APOE ε4 may be
advantageous in infections with pathogens requiring
host lipid for survival. The high affinity ε4 has for
some lipids actually hindered their uptake by the
pathogen (Martin, 1999). Thus, the ε4 allele may
be advantageous to the Yoruba where infectious
disease stills plays an important role in health.
On the other hand, under certain environmental
conditions such as a high fat diet and low physical
activity, individuals who carry an ε4 allele will have
higher risk of mortality and disease due to higher
cholesterol levels.
In addition, the strong association observed in
the African American cohort may be a result of
admixture. Admixture refers to the mixed ancestry,
both African and Caucasian, which is typically
observed among individuals who are African
American. It is hypothesized that the effect of the
APOE ε4 allele in African American populations
may be due to its Caucasian ancestry. Evaluation
of this hypothesis, as well as the potential effect
of unique African variants modifying the effect
of the APOE e4 allele, can be best evaluated
using whole genome sequencing data in these two
populations.
There are many environmental and life style
differences between the Yoruba and the African
Americans (Hendrie et al., 2004). For example
the Yoruba diet has been described as being low
in fat and low calorie (Hendrie et al., 2004).
Probably, as a consequence, the levels of cholesterol
and triglycerides are significantly lower in the
Yoruba than in the African Americans (Deeg et al.,
2008).
The role of cholesterol in the etiology of AD,
however, remains controversial (Reitz et al., 2013).
In a previous study we reported very similar
significant interactions between cholesterol levels,
APOE e4 and AD risk for both Yoruba and
African Americans (Evans et al., 2000; Hall et al.,
2006). However, in our study increasing levels of
cholesterol increased the risk for AD, but only
in those participants who did not possess an e4
allele. The risk associated with e4 remained lower
in Yoruba than in African Americans regardless
of cholesterol levels suggesting that the e4 link
to lipid metabolism maybe due to differences in
genes associated with lipid metabolism rather than
cholesterol levels per se.
It is noteworthy that the second major genetic
variant affecting AD risk in African Americans is
ABCA7, which mediates the biogenesis of high
density lipoproteins (Reitz et al., 2013). The authors
conclude that, together with the confirmation of
the effect of e4, their findings suggest that lipid
metabolism is a prominent pathway for Late Onset
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Alzheimer Disease in African Americans. The status
of ABCA7 and AD risk in African populations
remain untested however.
In our analysis of cognitive decline as an outcome
we find a similar pattern as with incident AD, with
the Indianapolis cohort showing a significant effect
for the possession of both a single and double copy
of an ε4 allele while the Yoruba cohort showed a
significant effect for the presence of an e4 allele
(p = 0.0425) but no significant effect for either
homozygosity or heterozygosity.
There is some evidence that the ε4 effect
on cognitive decline varies according to the
cognitive domain measured. Consistent with
previous reports, in our study, the association with
APOEe4 appears to be driven primarily by the
scores in the memory subdomain (Unverzagt et al.,
2011). Our African American findings are also
similar to previous studies that included African
American samples (Knopman et al., 2009; Sawyer
et al., 2009). As far as we can determine this
represents the first analysis of the effects of ε4 in
cognitive decline in an African population.
Strengths
The 19 year longitudinal Indianapolis Ibadan
Project is the largest and longest comparative study
of dementia that includes African and African
American cohorts. Results from the study represent
the most comprehensive analysis of the effects of
ε4 on incident AD and cognitive decline currently
reported with African populations.
Weaknesses
APOE analyses were conducted in approximately
half of the total sample. Participants in Ibadan who
did not have APOE genotyping were significantly
older while those in Indianapolis were significantly
less educated than those with APOE genotyping.
It is possible that the non-geno-typed samples
contained more AD patients and therefore this
analysis may underestimate the effects of APOE e4.
The Yoruba sample came from a circumscribed
geographical area. Caution should be used to
generalize these findings to the entire Nigerian
population.
The study used self or informant reports for
identifying co morbidities thus raising the possibility
that these were under reported particularly in
the Yoruba population. These, together with the
population biases described above, may account
for some surprising co morbidity findings such as
African Americans with incident AD being less
likely to have diabetes.
No information on individual diet or medication
was included in this study
The CSID is a relatively crude instrument to
measure cognitive decline.
In summary, the ε4 allele of APOE was strongly
related to increased risk for incident AD and
cognitive decline in African Americans while a
weaker but significant effect for incident AD was
only found for ε4 homozygosity and for the presence
of an e4 allele for cognitive decline in Yoruba.
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